- Home
- RERE vs NBTX Comparison
RERE vs NBTX Comparison
Compare RERE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- NBTX
- Stock Information
- Founded
- RERE 2011
- NBTX 2003
- Country
- RERE China
- NBTX France
- Employees
- RERE N/A
- NBTX N/A
- Industry
- RERE Other Specialty Stores
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- NBTX Health Care
- Exchange
- RERE Nasdaq
- NBTX Nasdaq
- Market Cap
- RERE 932.6M
- NBTX 868.8M
- IPO Year
- RERE 2021
- NBTX 2020
- Fundamental
- Price
- RERE $4.26
- NBTX $20.65
- Analyst Decision
- RERE
- NBTX Strong Buy
- Analyst Count
- RERE 0
- NBTX 1
- Target Price
- RERE N/A
- NBTX $8.00
- AVG Volume (30 Days)
- RERE 1.5M
- NBTX 119.0K
- Earning Date
- RERE 11-19-2025
- NBTX 09-30-2025
- Dividend Yield
- RERE N/A
- NBTX N/A
- EPS Growth
- RERE N/A
- NBTX N/A
- EPS
- RERE 0.12
- NBTX N/A
- Revenue
- RERE $2,588,775,650.00
- NBTX $11,930,711.00
- Revenue This Year
- RERE $30.66
- NBTX N/A
- Revenue Next Year
- RERE $25.12
- NBTX $74.67
- P/E Ratio
- RERE $35.70
- NBTX N/A
- Revenue Growth
- RERE 27.39
- NBTX N/A
- 52 Week Low
- RERE $2.00
- NBTX $2.76
- 52 Week High
- RERE $4.93
- NBTX $22.85
- Technical
- Relative Strength Index (RSI)
- RERE 45.42
- NBTX 72.61
- Support Level
- RERE $4.50
- NBTX $19.11
- Resistance Level
- RERE $4.78
- NBTX $22.64
- Average True Range (ATR)
- RERE 0.22
- NBTX 1.64
- MACD
- RERE -0.05
- NBTX 0.64
- Stochastic Oscillator
- RERE 15.83
- NBTX 84.58
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.